Highlights:
- Dr. Reddys Laboratories Ltd announced the launch of a generic version of Ciprodex in the US
- The Ciprodex brand had been estimated to have sales worth $453 million MAT in the United States in the last twelve months
- Ciprofloxacin 0.3 percent and Dexamethasone 0.1 percent Otic Suspension, USP, will be available as 7.5 ml filled in a 10 ml bottle
Dr. Reddys Laboratories Ltd announced the launch of a generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension in the United States after approval from the US Food and Drug Administration (USFDA).
About Ciprodex
Ciprodex is a drug used to treat particular types of infections caused by germs called bacteria in adults and children 6 months of age or older. This medication is only used to treat bacterial ear infections. It is used to treat middle ear infections in children with ear tubes, and outer ear infections (also known as swimmer’s ear) in children and adults. The drug contains a combination of ciprofloxacin and dexamethasone. It is mostly sold in the form of ear drops, works by stopping the growth of bacteria and reducing ear swelling and discomfort.
Marc Kikuchi, Chief Executive Officer of North America Generics, Dr. Reddy’s said in a release, “We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bringing affordable generic medicines to market for patients.”
The Ciprodex brand had been estimated to have sales worth $453 million MAT (moving annual turnover) in the United States in the last twelve months, according to Reddy’s market statistics. Dr. Reddys Ciprofloxacin 0.3 percent and Dexamethasone 0.1 percent Otic Suspension, USP, will be available as 7.5 ml filled in a 10 ml bottle, as per the companies statement.
